Date published: 2026-1-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

YadA Inhibitors

YadA inhibitors belong to a unique class of chemical compounds designed to target the YadA protein, which is primarily found in certain pathogenic bacteria. YadA, short for "Yersinia adhesin A," is a surface protein expressed by bacteria belonging to the Yersinia genus, such as Yersinia enterocolitica and Yersinia pseudotuberculosis. This protein plays a crucial role in the initial stages of host-pathogen interactions, as it functions as an adhesin and invasin, allowing the bacterium to adhere to host cells and facilitate its entry into the host organism. YadA is a significant virulence factor and contributes to the pathogenicity of these bacteria, making it an attractive target for the development of inhibitors.

YadA inhibitors are designed to disrupt the interaction between the YadA protein and host cells. These chemical compounds are typically small molecules that can bind to specific regions of the YadA protein, thereby blocking its adhesion to host cell receptors. By inhibiting this crucial step in the infection process, YadA inhibitors impedes the ability of Yersinia bacteria to establish infections and cause diseases in the host. The development of YadA inhibitors represents a promising avenue in the field of anti-infective research, as it offers a strategy to combat Yersinia infections at their root, by targeting a fundamental aspect of the pathogen's virulence. This class of compounds is the subject of ongoing research aimed at better understanding their mechanism of action and optimizing their effectiveness in combating Yersinia-associated diseases.

SEE ALSO...

Items 1 to 10 of 23 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

PI3K inhibitor targeting the PI3K/Akt pathway, suppressing downstream signaling cascades that regulate YadA expression.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits BCR-ABL tyrosine kinase, used in leukemia

Tamoxifen

10540-29-1sc-208414
2.5 g
$272.00
18
(2)

Selective estrogen receptor modulator (SERM) to block breast cancer

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Blocks PI3K activity, disrupting the PI3K/Akt pathway, ultimately leading to inhibition of YadA expression and function.

Ritonavir

155213-67-5sc-208310
10 mg
$124.00
7
(1)

Protease inhibitor, used in HIV therapy to block viral replication.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

mTOR inhibitor impacting the mTOR pathway, which regulates protein translation and YadA synthesis, resulting in inhibition.

A66

1166227-08-2sc-364394
sc-364394A
5 mg
50 mg
$255.00
$1455.00
(0)

Akt inhibitor disrupting the PI3K/Akt pathway, consequently down-regulating YadA expression through Akt inhibition.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Multikinase inhibitor targeting Raf, VEGFR, and PDGFR in cancer therapy.

MK-2206 dihydrochloride

1032350-13-2sc-364537
sc-364537A
5 mg
10 mg
$182.00
$332.00
67
(1)

Allosteric Akt inhibitor, blocking the PI3K/Akt pathway and hindering YadA expression by inhibiting downstream signaling.

Omeprazole

73590-58-6sc-202265
50 mg
$67.00
4
(1)

Proton pump inhibitor, reduces gastric acid secretion for ulcers and GERD.